MicroRNAs and histone deacetylase inhibition-mediated protection against inflammatory β-cell damage

PLoS One. 2018 Sep 27;13(9):e0203713. doi: 10.1371/journal.pone.0203713. eCollection 2018.

Abstract

Inflammatory β-cell failure contributes to type 1 and type 2 diabetes pathogenesis. Pro-inflammatory cytokines cause β-cell dysfunction and apoptosis, and lysine deacetylase inhibitors (KDACi) prevent β-cell failure in vitro and in vivo, in part by reducing NF-κB transcriptional activity. We investigated the hypothesis that the protective effect of KDACi involves transcriptional regulation of microRNAs (miRs), potential new targets in diabetes treatment. Insulin-producing INS1 cells were cultured with or without the broad-spectrum KDACi Givinostat, prior to exposure to the pro-inflammatory cytokines IL-1β and IFN-γ for 6 h or 24 h, and miR expression was profiled with miR array. Thirteen miRs (miR-7a-2-3p, miR-29c-3p, miR-96-5p, miR-101a-3p, miR-140-5p, miR-146a-5p, miR-146b-5p, miR-340-5p, miR-384-5p, miR-455-5p, miR-466b-2-3p, miR-652-5p, and miR-3584-5p) were regulated by both cytokines and Givinostat, and nine were examined by qRT-PCR. miR-146a-5p was strongly regulated by cytokines and KDACi and was analyzed further. miR-146a-5p expression was induced by cytokines in rat and human islets. Cytokine-induced miR-146a-5p expression was specific for INS1 and β-TC3 cells, whereas α-TC1 cells exhibited a higher basal expression. Transfection of INS1 cells with miR-146a-5p reduced cytokine signaling, including the activity of NF-κB and iNOS promoters, as well as NO production and protein levels of iNOS and its own direct targets TNF receptor associated factor 6 (TRAF6) and interleukin-1 receptor-associated kinase 1 (IRAK1). miR-146a-5p was elevated in the pancreas of diabetes-prone BB-DP rats at diabetes onset, suggesting that miR-146a-5p could play a role in type 1 diabetes development. The miR array of cytokine-exposed INS1 cells rescued by KDACi revealed several other miRs potentially involved in cytokine-induced β-cell apoptosis, demonstrating the strength of this approach.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Animals
  • Apoptosis
  • Cell Line
  • Cytokines / metabolism
  • Diabetes Mellitus / genetics*
  • Diabetes Mellitus / metabolism
  • Female
  • Gene Expression Regulation
  • Histone Deacetylase Inhibitors / pharmacology*
  • Humans
  • Insulin-Secreting Cells / cytology
  • Insulin-Secreting Cells / physiology*
  • Islets of Langerhans / metabolism
  • Male
  • MicroRNAs / physiology*
  • Middle Aged
  • NF-kappa B / genetics
  • NF-kappa B / metabolism
  • Rats
  • Rats, Wistar

Substances

  • Cytokines
  • Histone Deacetylase Inhibitors
  • MicroRNAs
  • NF-kappa B

Grants and funding

This work was supported by the Independent Research Fund Denmark (ALV, TMP; https://ufm.dk/en/research-and-innovation/councils-and-commissions/independent-research-fund-Denmark), the Novo Nordisk Foundation (ALV, TMP; http://novonordiskfonden.dk/en), the Danish Diabetes Association (FP; https://diabetes.dk/diabetesforeningen/inenglish/the-danish-diabetes-association.aspx), the Desirée and Niels Yde Foundation (ALV, TMP), the A.P. Møller Foundation (ALV, TMP, CHBB; https://www.apmollerfonde.dk/), Novo Nordisk A/S (KSF), the Poul and Erna Sehested Hansen Foundation (CHBB, ALV), the Sven Hansen and wife Ina Hansen Foundation (ALV), and the Danish Strategic Research Council (FP; https://ufm.dk/en/research-and-innovation/councils-and-commissions/the-danish-council-for-research-and-innovation-policy/the-danish-council-for-research-policy) by funding the Center for non-coding RNA in Technology and Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The commercial company Novo Nordisk A/S provided support in the form of salaries for authors [ALV, KSF], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.